The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study

M Gueguen, L Khatchatourian, C Lohéac, I Dorval, M Mercier, R Le Calloch, K Mahé, M J Rizcallah, P Hutin, M S Fangous, N Saidani, L Le Clech, M Gueguen, L Khatchatourian, C Lohéac, I Dorval, M Mercier, R Le Calloch, K Mahé, M J Rizcallah, P Hutin, M S Fangous, N Saidani, L Le Clech

Abstract

Objectives: The HEMVACO study evaluated the humoral response after mRNA anti-SARS-CoV-2 vaccination in an hematological cohort.

Methods: HEMVACO was a prospective, multicentric study registered in ClinicalTrials.gov, number NCT04852796. Patients received two or three doses of BNT162b2 vaccine or mRNA-1273 vaccine. The SARS-CoV-2 TrimericS IgG titers were measured 1, 3, 6 and 12 months after the second dose.

Results: Only 16 patients (11.6%) were naive of hematological treatment and 77 patients (55.8%) were on active treatment for hemopathy. Among the 138 analyzed patients, positive antibody titer at 1 month was obtained in 68.1% of patients with mean serology at 850±883 BAU/ml. Risk factors for vaccine failure were anti-CD20 therapy (OR=111[14.3-873]; P<0.001), hypogammaglobulinemia under 8g/L (OR=2.49[1.05-5.92]; P=0.032) and lymphopenia under 1.5G/L (OR=2.47[1.18-5.17]; P=0.015). Anti-CD20 therapy induced no anti-SARS-CoV-2 seroconversion (96%). Seventy-eight patients (56.5%) received a third dose and could reach the SARS-CoV-2 TrimericS IgG titer of high-risk patients (P=0.54). The median titer at 379 BAU/ml distinguished two groups of vaccine response (99±121 BAU/ml versus 1,109±678 BAU/ml).

Conclusion: Vaccination should be performed before anti-CD20 therapy if the hemopathy treatment can be delayed. Administration of the third vaccine dose was interesting for patients with suboptimal response, defined by a 379 BAU/ml titer in our study.

Keywords: Anti-CD20 monoclonal antibody; Booster immunization; Hematologic diseases; Hypogammaglobulinemia; SARS-CoV-2 vaccine.

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Figures

Fig. 1
Fig. 1
Distribution of anti-Trimeric Spike protein (mean) titers at 1 month, according to the risk factors for severe COVID-19 disease. Very high risk patients were represented by auto or allogeneic stem cell transplant, lymphoid hemopathy (lymphoma, myeloma), in particular treated by anti-CD20 antibody, Burton tyrosine inhibitors or CAR-T cells, and primary immunodeficiency diseases. High-risk patients were represented by other hematological diseases or non-immunosuppressive therapy.
Fig. 2
Fig. 2
Anti-Trimeric Spike protein (mean) titers evolution. Very high-risk patients received three doses of mRNA COVID-19 vaccine (auto or allogeneic stem cell transplant, lymphoid hemopathy [lymphoma, myeloma], in particular treated by anti-CD20 antibody, Burton tyrosine inhibitors or CAR-T cells, and primary immunodeficiency diseases). The mean (± SD) anti-Trimeric Spike protein were 371 (± 641), 249 (±493) and 557 (±776) BAU/mL at 1, 3 and 6 months respectively, for 77, 50 and 40 patients, respectively. High-risk patients received two doses of mRNA COVID-19 vaccine and were represented by other hematological diseases or non-immunosuppressive therapy. The mean (± SD) anti-Trimeric Spike protein were 1,504 (±756), 1,056 (±784) and 689 (±778) BAU/mL at 1, 3 and 6 months respectively, for 61, 59 and 18 patients, respectively.

References

    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet Lond Engl. 2020;395(10223):497–506.
    1. Borah P., Mirgh S., Sharma S.K., Bansal S., Dixit A., Dolai T.K., et al. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis. 2021;87:102525.
    1. Houot R., Levy R., Cartron G., Armand P. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer Oxf Engl 1990. 2020;136:4–6.
    1. van der Kolk L.E., Baars J.W., Prins M.H., van Oers M.H.J. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257–2259.
    1. Sun C., Pleyer C., Wiestner A. COVID-19 vaccines for patients with haematological conditions. Lancet Haematol. 2021;8(5):e312–e314.
    1. Terpos E., Trougakos I.P., Gavriatopoulou M., Papassotiriou I., Sklirou A.D., Ntanasis-Stathopoulos I., et al. Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose. Blood. 2021;137(26):3674–3676. doi: 10.1182/blood.2021011904.
    1. Ministère des solidarités et de la santé; Conseil d’Orientation de la Stratégie Vaccinale; Note du 13 janvier 2021 relative à la vaccination en très haute priorité des personnes à très haut risque; .
    1. Ministère des solidarités et de la santé; Conseil d’Orientation de la Stratégie Vaccinale; Avis du 6 avril 2021: Élargissement des priorités d’accès à la vaccination anti-Covid-19 - mise à jour du 7 mai 2021. .
    1. Herishanu Y., Avivi I., Aharon A., Shefer G., Levi S., Bronstein Y., et al. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. Blood. 2021;137(23):3165–3173. doi: 10.1182/blood.2021011568.
    1. Turner J.S., O’Halloran J.A., Kalaidina E., Kim W., Schmitz A.J., Zhou J.Q., et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596(7870):109–113.
    1. Stankov M.V., Cossmann A., Bonifacius A., Dopfer-Jablonka A., Ramos G.M., Gödecke N., et al. Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021;73(11):2000–2008. doi: 10.1093/cid/ciab555.
    1. Favresse J., Bayart J.-L., Mullier F., Elsen M., Eucher C., Van Eeckhoudt S., et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021;10(1):1495–1498.
    1. Doria-Rose N., Suthar M.S., Makowski M., O’Connell S., McDermott A.B., Flach B., et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021;384(23):2259–2261.
    1. Feng S., Phillips D.J., White T., Sayal H., Aley P.K., Bibi S., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–2040. doi: 10.1038/s41591-021-01540-1. [Epub 2021 Sep 29]
    1. Werbel W.A., Boyarsky B.J., Ou M.T., Massie A.B., Tobian A.A.R., Garonzik-Wang J.M., et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med. 2021;174(9):1330–1332. doi: 10.7326/L21-0282. [Epub 2021 Jun 15]
    1. Falsey A.R., Frenck R.W., Walsh E.E., Kitchin N., Absalon J., Gurtman A., et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021;385(17):1627–1629.
    1. Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745.
    1. O’Brien M.P., Forleo-Neto E., Musser B.J., Isa F., Chan K.-C., Sarkar N., et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med. 2021;385(13):1184–1195. doi: 10.1056/NEJMoa2109682. [Epub 2021 Aug 4]
    1. Thompson M.A., Henderson J.P., Shah P.K., Rubinstein S.M., Joyner M.J., Choueiri T.K., et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021;7(8):1167–1175. doi: 10.1001/jamaoncol.2021.1799.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa